

**Supplementary Table S1.** Previous studies on cyclin D1 expression in SIACs and CRCs.

Study	Country (yr)	IHC	N	Clone used	Cyclin D1 <sup>High</sup>		Outcome
					Cut-off level	N (%)	Survival
SIACs							
Present	Korea	TMA	232	SP4	Score >3.5	145 (62.5)	Better OS
Aber [22]	USA (1999)	Whole section	24	Non-SP4 <sup>a</sup>	≥ 10%	24 (30.0)	Decreased 3YSR
CRCs							
Jun [18]	Korea (2022)	TMA	495	SP4	Score ≥ 1	389 (78.6)	Better OS and RFS
Jang [28]	Korea (2012)	TMA	217	SP4	≥ 30%	158 (72.5)	Better OS and RFS
Ogino [29]	USA (2009)	TMA	602	SP4	> 50%	330 (54.8)	Better CSS
Seicean [30]	Romania (2011)	TMA	87	SP4	> 10%	47 (54.0)	Not significant
Stor [31]	Slovenia (2008)	TMA	191	SP4	NS	NS	Not significant
Hilska [32]	Finland (2005)	TMA	363	P2D11F11	≥ 1%	99 (27.3)	Better OS
McKay [33]	UK (2002)	Whole section	249	P2D11F11	> 5%	137 (55.0)	Better OS
Von Stockmar-Von Wangenheim [34]	Germany (2008)	Whole section	200	P2D11F11	> 5%	150 (75.0)	Not significant
Lyll [35]	UK (2006)	Whole section	90	P2D11F11	> 5%	46 (51.1)	Not significant
McKay [36]	UK (2000)	Whole section	100	P2D11F11	> 50%	8 (8.0)	Worse OS
Bhatavdekar [37]	India (2001)	Whole section	98	P2D11F11	≥ 1%	30 (30.6)	Worse OS
Bahnassy [38]	Egypt (2004)	Whole section	60	DCS-6	Index ≥ 6.1	41 (68.3)	Worse OS
Moore [39]	USA (2004)	Whole section	40	DCS-6	> 10%	6 (15.0)	Not significant
Holland [40]	UK (2001)	Whole section	126	DCS-6	> 10%	74 (58.7)	Better OS
Maeda [41]	Japan (1998)	Whole section	123	Non-SP4 <sup>a</sup>	> 50%	20 (16.3)	Worse OS and DFS
Maeda [42]	Japan (1997)	Whole section	101	Non-SP4 <sup>a</sup>	> 50%	14 (13.9)	Worse DFS
Tsai [43]	Taiwan (2013)	Whole section	100	NS	Score ≥ 2	49 (49.0)	Not significant
Belt [44]	Netherlands (2012)	TMA	379	NS	Score ≥ 8	211 (55.7)	Not significant
Mao [45]	China (2011)	Whole section	169	NS	5%	95 (56.2)	Worse OS
Fang [46]	China (2009)	TMA	532	NS	≥ 10%	380 (71.4)	Not significant
Kouraklis [47]	Greece (2006)	Whole section	111	NS	> 5%	71 (63.9)	Not significant
Bondi [48]	Norway (2005)	Whole section	219	NS	≥ 5%	24 (11.0)	Not significant
Bondi [49]	Norway (2004)	Whole section	162	NS	> 5%	NS	Not significant

Small intestinal adenocarcinoma (SIAC); colorectal carcinoma (CRC); high expression of cyclin D1 (cyclin D1<sup>High</sup>); immunohistochemistry (IHC); tissue microarray (TMA); overall survival (OS); year-survival rate (YSR); recurrence-free survival (RFS); cancer specific survival (CSS); not stated (NS); disease-free survival (DFS).; <sup>a</sup>Among reports that did not precisely define the clones, three studies before novel SP4 was developed in 2004 were considered to use non-SP4.